Australian pharma warns TGA against removing fee incentives for orphan drugs
This article was originally published in SRA
Australia's pharmaceutical industry association, Medicines Australia, has objected to proposals by the Therapeutic Goods Administration to eliminate fee waivers for the registration and evaluation of orphan drugs1. The association warns that if this incentive is removed, "local sponsors may not invest in bringing these products to market in Australia as this would not be commercially viable in many instances".
Register for our free email digests: